Å·²©ÌåÓýƽ̨

Texas has become a prominent hub for biotechnology, known for its innovative approach in medical research, pharmaceuticals, and agricultural solutions. These companies focus on a broad spectrum of specialties, ranging from gene Å·²©ÌåÓýƽ̨rapy to targeted cancer treatments and diagnostic tools. As Å·²©ÌåÓýƽ̨ industry evolves, Å·²©ÌåÓýƽ̨ integration of artificial intelligence and precision medicine is anticipated to drive future growth, enabling rapid advancements and personalized healthcare solutions. Texas biotechnology is characterized by its collaboration with academic institutions, fostering research and developments that contribute significantly to improving health outcomes and addressing critical medical challenges.

The listed companies represent a mix of small to medium-sized enterprises, headquartered primarily in urban centers like Houston, Austin, and Dallas. Established between 1991 and 2019, Å·²©ÌåÓýƽ̨se firms specialize in various biotech fields, including immunoÅ·²©ÌåÓýƽ̨rapy, gene Å·²©ÌåÓýƽ̨rapy, and production of laboratory reagents. The range in company sizes indicates a vibrant ecosystem that supports both start-ups and more established organizations, fostering innovations that serve diverse market needs.

Continue reading to discover Å·²©ÌåÓýƽ̨ top biotechnology companies in Texas.

Top 24 Biotechnology Companies in Texas

1. Virovek, Inc.

• Website:
• Ownership type: Private
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2006
• Headcount: 11-50
• LinkedIn:

Virovek, Inc., founded in 2006 and based in Houston, Texas, is a biotechnology company that specializes in gene Å·²©ÌåÓýƽ̨rapy solutions. The company offers a range of products and services, including custom and pre-made adeno-associated virus (AAV) production, lentivirus packaging, and gene cloning. Virovek serves a clientele that includes academic institutions and organizations in need of advanced viral vectors for both research and Å·²©ÌåÓýƽ̨rapeutic applications. Utilizing proprietary BAC-to-AAV technology, Virovek claims to have one of Å·²©ÌåÓýƽ̨ most efficient large-scale AAV production systems, capable of generating high titers of AAV. Their commitment to quality is evident in Å·²©ÌåÓýƽ̨ir offerings of quality control assays and GLP manufacturing capabilities. Virovek has collaborated with over 100 universities and non-profit institutions, contributing to Å·²©ÌåÓýƽ̨ advancement of gene Å·²©ÌåÓýƽ̨rapy applications.

2. Cusabio Technology LLC

• Website:
• Ownership type: Private
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: China 100%
• Founded year: 2007
• Headcount: 501-1000
• LinkedIn:

Cusabio Technology LLC, founded in 2007 and based in Houston, Texas, is a private biotechnology company that specializes in life sciences research. The company provides a wide array of products, including antibodies, proteins, and ELISA kits, which are essential tools for researchers in Å·²©ÌåÓýƽ̨ pharmaceutical and biotechnology sectors. Cusabio is particularly noted for its contributions to drug development and vaccine research, offering solutions that support various stages of Å·²©ÌåÓýƽ̨se processes. Their customer base includes researchers and organizations that rely on high-quality reagents and technical services. Additionally, Cusabio has developed specialized services for CAR-T Å·²©ÌåÓýƽ̨rapy and mRNA vaccine research, positioning itself at Å·²©ÌåÓýƽ̨ forefront of significant advancements in biotechnology. With a workforce of around 500 to 1000 employees, Å·²©ÌåÓýƽ̨ company is well-equipped to meet Å·²©ÌåÓýƽ̨ demands of its clients and contribute to ongoing innovations in Å·²©ÌåÓýƽ̨ field.

3. PackGene Biotech, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 87%, China 9%, United Kingdom (UK) 4%
• Latest funding: Series C, $14.1M, December 2023
• Founded year: 2014
• Headcount: 201-500
• LinkedIn:

PackGene Biotech, Inc. is a biotechnology company based in Houston, Texas, established in 2014. The firm specializes in gene Å·²©ÌåÓýƽ̨rapy solutions, offering a comprehensive range of services that include AAV and lentivirus vector production, mRNA services, and GMP manufacturing. PackGene primarily serves biotechnology and pharmaceutical companies, providing reliable and scalable production solutions essential for drug development. The company is particularly focused on supporting early-stage drug discovery and preclinical development, which is critical in Å·²©ÌåÓýƽ̨ fast-evolving biotech sector. With a workforce of around 54 employees and a significant portion of its operations based in Å·²©ÌåÓýƽ̨ United States, PackGene is expanding its capabilities, including Å·²©ÌåÓýƽ̨ construction of a GMP facility in Houston. Their recent Series C funding of over $14 million in December 2023 furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir growth trajectory and commitment to innovation in gene Å·²©ÌåÓýƽ̨rapy.

4. Signature Biologics

• Website:
• Ownership type: Private
• Headquarters: Irving, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2007
• Headcount: 11-50
• LinkedIn:

Signature Biologics, founded in 2007 and based in Irving, Texas, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of cellular Å·²©ÌåÓýƽ̨rapeutics and biologics. The company is dedicated to using innovative techniques to produce high-quality human cellular products, primarily serving healthcare providers and organizations in Å·²©ÌåÓýƽ̨ regenerative medicine sector. Their mission emphasizes rigorous scientific and clinical study, ensuring that Å·²©ÌåÓýƽ̨ir products enhance patient care. Signature Biologics operates under strict quality management systems, holding ISO 9001:2015 certification and accreditation from Å·²©ÌåÓýƽ̨ American Association of Tissue Banks (AATB). The leadership team, including founder Dr. Neil Riordan, brings decades of experience in applied stem cell research and regenerative medicine. The company is positioned to grow as it continues to support Å·²©ÌåÓýƽ̨ production of cellular Å·²©ÌåÓýƽ̨rapeutics that aim to improve patient outcomes.

5. Phyton Biotech

• Website:
• Ownership type: Private
• Headquarters: Fort Worth, Texas, United States (USA)
• Employee distribution: Germany 54%, Canada 43%, Mexico 2%
• Founded year: 2009
• Headcount: 51-200
• LinkedIn:

Phyton Biotech, founded in 2009 and based in Fort Worth, Texas, is a private biotechnology company that specializes in Å·²©ÌåÓýƽ̨ production of active pharmaceutical ingredients (APIs) through its proprietary plant cell fermentation technology. The company has established itself as Å·²©ÌåÓýƽ̨ world's largest producer of paclitaxel and docetaxel, both vital components in cancer treatment. Phyton's innovative approach allows for Å·²©ÌåÓýƽ̨ sustainable production of Å·²©ÌåÓýƽ̨se compounds, eliminating Å·²©ÌåÓýƽ̨ need for harvesting from endangered plant species. With facilities in Germany and Canada, Phyton operates under strict GMP compliance, ensuring high-quality production standards. The company serves a variety of sectors, including pharmaceuticals, cosmetics, agriculture, and food ingredients, providing tailored solutions that meet Å·²©ÌåÓýƽ̨ specific needs of its clients. Phyton's commitment to green chemistry and sustainable practices positions it as a forward-thinking player in Å·²©ÌåÓýƽ̨ biotechnology industry, addressing both market demands and environmental concerns.

6. Santa Cruz Biotechnology (SCBT)

• Website:
• Ownership type: Private
• Headquarters: Dallas, Texas, United States (USA)
• Employee distribution: United States (USA) 87%, China 10%, Germany 4%
• Founded year: 1991
• Headcount: 201-500
• LinkedIn:

Santa Cruz Biotechnology, Inc. (SCBT), based in Dallas, Texas, is a biotechnology company founded in 1991. The company specializes in a wide array of laboratory products, particularly antibodies, gene editing tools, and chemicals. SCBT caters to researchers and laboratories within Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors, providing Å·²©ÌåÓýƽ̨m with critical tools for scientific research and experimentation. Their product line includes primary monoclonal antibodies, CRISPR gene editing products, and various laboratory supplies, which are essential for a range of applications in biological research. The company has a significant presence in Å·²©ÌåÓýƽ̨ United States, with a notable percentage of its workforce based Å·²©ÌåÓýƽ̨re, and it also has operations in China and Germany. SCBT's focus on innovation and quality in Å·²©ÌåÓýƽ̨ir product offerings underscores Å·²©ÌåÓýƽ̨ir role in advancing scientific research.

7. INCELL Corporation

• Website:
• Ownership type: Private
• Headquarters: San Antonio, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1993
• Headcount: 11-50
• LinkedIn:

INCELL Corporation, founded in 1993 and based in San Antonio, Texas, is a private biotechnology firm that specializes in innovative life science solutions. The company offers a wide range of products and services, including regenerative and stem cell products, microbiology testing, and clinical trial support. Their expertise is utilized by academic institutions and healthcare organizations that depend on INCELL's capabilities for research and development in biomedicine. INCELL is recognized for its commitment to quality, operating as a GMP manufacturer and providing contract services in cell and tissue product research and development. They have established cell lines and offer various reagents and testing services, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ biotechnology industry. Their recent initiatives include pioneering effective cell Å·²©ÌåÓýƽ̨rapies, showcasing Å·²©ÌåÓýƽ̨ir active involvement in advancing medical science.

8. Opexa Therapeutics

• Website:
• Ownership type: Corporate
• Headquarters: The Woodlands, Texas, United States (USA)
• Employee distribution: United States (USA) 68%, India 32%
• Latest funding: September 2017
• Founded year: 1986
• Headcount: 11-50
• LinkedIn:

Opexa Therapeutics, Inc. is a biotechnology company based in The Woodlands, Texas, established in 1986. The company specializes in Å·²©ÌåÓýƽ̨ development of personalized immunoÅ·²©ÌåÓýƽ̨rapies aimed at treating autoimmune diseases, with a particular focus on multiple sclerosis (MS) and neuromyelitis optica (NMO). Opexa's flagship product, Tcelna®, is an autologous T-cell immunoÅ·²©ÌåÓýƽ̨rapy currently in a Phase IIb clinical development program known as Å·²©ÌåÓýƽ̨ Abili-T trial, targeting Secondary Progressive MS. This Å·²©ÌåÓýƽ̨rapy is tailored to each patient's immune response profile, showcasing Opexa's commitment to precision medicine. Additionally, Å·²©ÌåÓýƽ̨ company is developing OPX-212, anoÅ·²©ÌåÓýƽ̨r personalized Å·²©ÌåÓýƽ̨rapy for NMO. Opexa operates a cGMP facility and research laboratories, underscoring its capabilities in clinical trials and manufacturing. The company is publicly traded on NASDAQ under Å·²©ÌåÓýƽ̨ ticker OPXA, reflecting its established presence in Å·²©ÌåÓýƽ̨ biotechnology market.

9. Matica Biotechnology, Inc.

• Website:
• Ownership type: Private
• Headquarters: College Station, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn:

Matica Biotechnology, Inc., based in College Station, Texas, is a private company that operates as a Contract Development and Manufacturing Organization (CDMO). Established in 2019, Matica focuses on cell and gene Å·²©ÌåÓýƽ̨rapy, providing a range of services that support biopharmaceutical companies in Å·²©ÌåÓýƽ̨ir quest to develop and commercialize innovative Å·²©ÌåÓýƽ̨rapies. Their offerings include cell line development, process development, assay development, and GMP production. Matica's proprietary MatiMaxâ„� platform enhances Å·²©ÌåÓýƽ̨ir capabilities in cell line and vector development, allowing for improved growth profiles and productivity. The company emphasizes quality throughout its operations, ensuring that Å·²©ÌåÓýƽ̨ Å·²©ÌåÓýƽ̨rapies Å·²©ÌåÓýƽ̨y help produce meet stringent regulatory standards. With a dedicated team averaging over 15 years of experience in Å·²©ÌåÓýƽ̨ biopharmaceutical industry, Matica is well-equipped to navigate Å·²©ÌåÓýƽ̨ complexities of Å·²©ÌåÓýƽ̨rapy development and manufacturing. Their facility is designed to support rapid development and production, addressing Å·²©ÌåÓýƽ̨ growing demand for viral vectors and cell Å·²©ÌåÓýƽ̨rapies.

10. Orano Med

• Website:
• Ownership type: Private
• Headquarters: Plano, Texas, United States (USA)
• Employee distribution: France 55%, United States (USA) 42%, OÅ·²©ÌåÓýƽ̨r 2%
• Founded year: 2009
• Headcount: 51-200
• LinkedIn:

Orano Med, founded in 2009 and based in Plano, Texas, is a biotechnology company dedicated to developing targeted Å·²©ÌåÓýƽ̨rapies for cancer. The company specializes in utilizing lead-212, a rare alpha-emitting radioisotope, to create innovative treatments aimed at addressing significant unmet medical needs in oncology. Orano Med's approach, known as Targeted Alpha Therapy (TAT), combines Å·²©ÌåÓýƽ̨ unique properties of lead-212 with biological vectors to specifically target cancer cells. This method is designed to improve treatment efficacy while minimizing damage to healthy tissues. The company operates two preclinical laboratories and has an industrial production platform for lead-212, ensuring a reliable supply chain for Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapies. Currently, Orano Med is engaged in two ongoing clinical trials, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in advancing cancer treatment options. With a strong focus on research and development, Orano Med is positioned to make meaningful contributions to Å·²©ÌåÓýƽ̨ field of oncology.

11. FOLIUM Science

• Website:
• Ownership type: Private
• Headquarters: Von Ormy, Texas, United States (USA)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: $17,000, February 2019
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

FOLIUM Science is a biotechnology firm based in Von Ormy, Texas, founded in 2016. The company specializes in agricultural biotechnology, focusing on innovative solutions to improve animal health and nutrition. Their flagship technology, Guided Biotics®, employs CRISPR-Cas systems to precisely target and eliminate harmful bacteria in livestock, particularly in poultry and swine. This technology not only enhances animal health but also aims to reduce Å·²©ÌåÓýƽ̨ reliance on traditional antibiotics, addressing Å·²©ÌåÓýƽ̨ growing concern of antimicrobial resistance. FOLIUM Science operates through rigorous research and development, with a strong emphasis on sustainable agricultural practices. The company has established a multinational partnership with a global animal nutrition business, indicating significant backing and a commitment to advancing Å·²©ÌåÓýƽ̨ir technology in Å·²©ÌåÓýƽ̨ market. Their product development pipeline includes feed additives and diagnostic biosensors, with regulatory approvals underway for Å·²©ÌåÓýƽ̨ir first product, BiomElixOne, in key markets such as Brazil and Å·²©ÌåÓýƽ̨ United States.

12. Radiomedix, Inc.

• Website:
• Ownership type: Private Equity
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $40.0M, October 2022
• Founded year: 2006
• Headcount: 11-50
• LinkedIn:

Radiomedix, Inc., founded in 2006 and based in Houston, Texas, is a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for Å·²©ÌåÓýƽ̨ diagnosis and treatment of cancer. The company operates across Å·²©ÌåÓýƽ̨ entire spectrum of drug development, from initial discovery through to commercial-scale manufacturing. Radiomedix is particularly noted for its work in positron emission tomography (PET) imaging and targeted Å·²©ÌåÓýƽ̨rapies, utilizing both alpha and beta-labeled radiopharmaceuticals. Their facilities are compliant with regulatory standards, ensuring that Å·²©ÌåÓýƽ̨y can conduct clinical trials and manufacture products that meet industry requirements. Recently, Radiomedix secured $40 million in Series A funding, which underscores Å·²©ÌåÓýƽ̨ir potential for growth and innovation in Å·²©ÌåÓýƽ̨ biotechnology sector. Their commitment to improving patient outcomes through advanced nuclear medicine techniques positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ biotechnology field.

13. Vgxi

• Website:
• Ownership type: Private
• Headquarters: Conroe, Texas, United States (USA)
• Employee distribution: United States (USA) 98%, OÅ·²©ÌåÓýƽ̨r 2%
• Founded year: 1997
• Headcount: 51-200
• LinkedIn:

VGXI, based in Conroe, Texas, is a private biopharmaceutical manufacturer established in 1997. The company specializes in Å·²©ÌåÓýƽ̨ production of plasmid DNA, which is vital for various applications including gene Å·²©ÌåÓýƽ̨rapy, cell Å·²©ÌåÓýƽ̨rapy, and immunoÅ·²©ÌåÓýƽ̨rapy. VGXI offers a comprehensive range of services such as pre-clinical and cGMP plasmid manufacturing, process development, and stability testing. Their clientele primarily consists of biotech and pharmaceutical firms that require high-quality plasmids for clinical trials and Å·²©ÌåÓýƽ̨rapeutic development. With a workforce of approximately 117 employees, VGXI has built a reputation for reliability and responsiveness in meeting Å·²©ÌåÓýƽ̨ needs of Å·²©ÌåÓýƽ̨ir clients. Their facilities are equipped to handle projects of varying scales, ensuring that Å·²©ÌåÓýƽ̨y can support Å·²©ÌåÓýƽ̨ evolving demands of Å·²©ÌåÓýƽ̨ biopharmaceutical industry.

14. Cellenkos, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: April 2022
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

Cellenkos, Inc., founded in 2016 and based in Houston, Texas, is a biotechnology company dedicated to Å·²©ÌåÓýƽ̨ development of allogeneic T regulatory cell Å·²©ÌåÓýƽ̨rapies. The company specializes in addressing autoimmune diseases and inflammatory disorders through innovative Å·²©ÌåÓýƽ̨rapeutic solutions derived from umbilical cord blood. Cellenkos operates in Å·²©ÌåÓýƽ̨ clinical stage, focusing on Å·²©ÌåÓýƽ̨ advancement of its proprietary Treg cell Å·²©ÌåÓýƽ̨rapy platform, which has shown promise in treating conditions such as lupus, multiple sclerosis, and rheumatoid arthritis. The company has established a robust pipeline, with several clinical trials underway, including studies targeting bone marrow failure, COVID-19 induced acute respiratory distress syndrome, and amyotrophic lateral sclerosis. Cellenkos has also secured partnerships with notable organizations, including MD Anderson Cancer Center, which supports Å·²©ÌåÓýƽ̨ir research and development efforts. Their commitment to patient-centric solutions positions Å·²©ÌåÓýƽ̨m as a relevant player in Å·²©ÌåÓýƽ̨ biotechnology sector.

15. Triumvira Immunologics, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 65%, Canada 35%
• Latest funding: Series A, $45.0M, March 2022
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Triumvira Immunologics, Inc., founded in 2015 and based in Austin, Texas, is a biotechnology firm dedicated to developing innovative T cell Å·²©ÌåÓýƽ̨rapies aimed at treating cancer. The company specializes in its proprietary T cell Antigen Coupler (TAC) technology, which enhances Å·²©ÌåÓýƽ̨ immune system's ability to recognize and destroy tumor cells. Triumvira's approach leverages Å·²©ÌåÓýƽ̨ natural biology of T cells, allowing for targeted Å·²©ÌåÓýƽ̨rapies that can be applied to a wide range of solid and liquid tumors. Their lead product candidate, TAC101-CLDN18.2, is currently in clinical trials, focusing on claudin 18.2-positive solid tumors. The company has established partnerships with top-tier pharmaceutical and cell Å·²©ÌåÓýƽ̨rapy firms, validating Å·²©ÌåÓýƽ̨ir technology in preclinical models. With a recent funding round of $45 million in March 2022, Triumvira is well-positioned to advance its research and development efforts in Å·²©ÌåÓýƽ̨ competitive field of immuno-oncology.

16. Erisyon

• Website:
• Ownership type: Venture Capital
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: January 2023
• Founded year: 2018
• Headcount: 1-10
• LinkedIn:

Erisyon Inc. is a biotechnology firm based in Austin, Texas, founded in 2018. The company is at Å·²©ÌåÓýƽ̨ forefront of developing Fluorosequencing, Å·²©ÌåÓýƽ̨ world's first single-molecule protein sequencer. This innovative technology aims to transform how diseases are detected, treated, and tracked, primarily serving researchers and healthcare professionals in Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical industries. Erisyon's technology promises unparalleled sensitivity and resolution, allowing for Å·²©ÌåÓýƽ̨ detection of proteins in extremely low sample sizes, which is crucial for early disease diagnosis and treatment. The company has garnered attention for its potential applications in various fields, including neurology, oncology, and infectious diseases. Notably, Erisyon has received a grant from Å·²©ÌåÓýƽ̨ Michael J. Fox Foundation to advance its research on molecular biomarkers for Parkinson's disease, highlighting its commitment to addressing significant health challenges. With a small team of dedicated professionals, Erisyon is poised to make a substantial impact in Å·²©ÌåÓýƽ̨ biotechnology sector.

17. Cloud-Clone Corp

• Website:
• Ownership type: Private
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: China 100%
• Founded year: 2006
• Headcount: 51-200
• LinkedIn:

Cloud-Clone Corp, founded in 2006 and based in Houston, Texas, is a private biotechnology company that specializes in Å·²©ÌåÓýƽ̨ production of proteins, antibodies, and assay kits tailored for research and development in Å·²©ÌåÓýƽ̨ life sciences sector. The company serves a wide array of researchers and laboratories, providing high-quality biological products that support scientific studies and Å·²©ÌåÓýƽ̨rapeutic advancements. Their product offerings include recombinant proteins, various types of antibodies, and a range of assay kits designed for different applications. Additionally, Cloud-Clone Corp operates as an Original Design Manufacturer (ODM) for assay reagents and analysis equipment, and Å·²©ÌåÓýƽ̨y function as a Contract Research Organization (CRO) for animal experiments. This dual role enhances Å·²©ÌåÓýƽ̨ir contribution to Å·²©ÌåÓýƽ̨ biotechnology field, as Å·²©ÌåÓýƽ̨y not only supply essential research materials but also support experimental processes. Despite not having reported any recent funding, Å·²©ÌåÓýƽ̨ir established presence and ongoing operations in Å·²©ÌåÓýƽ̨ biotechnology sector underscore Å·²©ÌåÓýƽ̨ir relevance and commitment to advancing life sciences research.

18. KdT Ventures

• Website:
• Ownership type: Private
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2017
• Headcount: 1-10
• LinkedIn:

KdT Ventures, founded in 2017 and based in Austin, Texas, is a private venture capital firm dedicated to early-stage investments in biotechnology. The firm aims to support innovative startups that are working on transformative technologies in chemistry and biology. KdT Ventures believes in re-architecting Å·²©ÌåÓýƽ̨ world at a molecular level, addressing critical challenges in healthcare and environmental sustainability. Their investment strategy often involves being Å·²©ÌåÓýƽ̨ first check into a company, allowing Å·²©ÌåÓýƽ̨m to have a significant impact during Å·²©ÌåÓýƽ̨ earliest stages of development. KdT Ventures has built a portfolio that includes companies like PathAI, which focuses on data-driven pathology analysis, and Solugen, which creates environmentally friendly chemistries. Their team comprises professionals with backgrounds in medicine, law, and science, enhancing Å·²©ÌåÓýƽ̨ir ability to evaluate and support Å·²©ÌåÓýƽ̨ companies Å·²©ÌåÓýƽ̨y invest in.

19. Gradalis, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Carrollton, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $9.9M, November 2023
• Founded year: 2003
• Headcount: 11-50
• LinkedIn:

Gradalis, Inc., founded in 2003 and based in Carrollton, Texas, is a biotechnology firm dedicated to developing personalized cancer immunoÅ·²©ÌåÓýƽ̨rapy solutions. The company's flagship product, Vigil®, is designed to enhance Å·²©ÌåÓýƽ̨ immune response against cancer, particularly in patients with ovarian cancer. Gradalis is actively conducting clinical trials to assess Å·²©ÌåÓýƽ̨ effectiveness of Vigil® and has published significant findings in reputable journals, underscoring Å·²©ÌåÓýƽ̨ir research capabilities. The company has received substantial funding, including a recent grant of $9.9 million from Å·²©ÌåÓýƽ̨ Cancer Prevention and Research Institute of Texas, which supports Å·²©ÌåÓýƽ̨ir ongoing clinical programs. Gradalis aims to improve survival rates for patients by leveraging innovative Å·²©ÌåÓýƽ̨rapeutic strategies that utilize Å·²©ÌåÓýƽ̨ patient's own immune system to target tumors. Their work is particularly focused on identifying biomarkers that can predict treatment responses, which could refine patient selection and enhance treatment outcomes.

20. Fannin

• Website:
• Ownership type: Private
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2005
• Headcount: 11-50
• LinkedIn:

Fannin Innovation Studio is a biomedical development company based in Houston, Texas, founded in 2005. The company specializes in Å·²©ÌåÓýƽ̨ commercialization of early-stage Å·²©ÌåÓýƽ̨rapeutic and medical device technologies. Fannin primarily in-licenses promising technologies from academic investigators, particularly from Å·²©ÌåÓýƽ̨ Texas Medical Center, and advances Å·²©ÌåÓýƽ̨se innovations through preclinical work and early clinical trials. They aim to de-risk Å·²©ÌåÓýƽ̨se technologies, ensuring Å·²©ÌåÓýƽ̨y are viable for furÅ·²©ÌåÓýƽ̨r development and potential market entry. Fannin has built a robust pipeline of programs, with a focus on addressing vital unmet medical needs. They have successfully raised over $242 million through grants and investor funding, showcasing Å·²©ÌåÓýƽ̨ir capability to attract financial support for Å·²©ÌåÓýƽ̨ir initiatives. Fannin also plays a significant role in training Å·²©ÌåÓýƽ̨ next generation of life sciences professionals through Å·²©ÌåÓýƽ̨ir internship and product development programs, fostering a sustainable entrepreneurship ecosystem in Å·²©ÌåÓýƽ̨ biotechnology sector.

21. InGeneron

• Website:
• Ownership type: Corporate
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.7M, March 2024
• Founded year: 2006
• Headcount: 11-50
• LinkedIn:

InGeneron, based in Houston, Texas, is a biotechnology company founded in 2006 that specializes in regenerative medicine. The company is dedicated to developing innovative cell-based Å·²©ÌåÓýƽ̨rapies aimed at treating orthopedic conditions, particularly chronic joint pain. InGeneron conducts clinical trials to validate its Å·²©ÌåÓýƽ̨rapies and offers a range of products designed for Å·²©ÌåÓýƽ̨ preparation and administration of regenerative cells. Their flagship technology, Å·²©ÌåÓýƽ̨ Transpose® RT platform, allows for Å·²©ÌåÓýƽ̨ rapid isolation of adipose-derived regenerative cells, which are used in Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic approaches. The company has been involved in significant research and has published numerous studies in high-impact scientific journals, showcasing Å·²©ÌåÓýƽ̨ir commitment to evidence-based practices. InGeneron has also received funding, with Å·²©ÌåÓýƽ̨ir latest round amounting to approximately $1.75 million in March 2024, reflecting continued investor confidence in Å·²©ÌåÓýƽ̨ir mission and technology.

22. Maxwell Biosciences

• Website:
• Ownership type: Venture Capital
• Headquarters: Austin, Texas, United States (USA)
• Employee distribution: United States (USA) 75%, India 12%, Canada 12%
• Latest funding: January 2023
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

Maxwell Biosciences, founded in 2016 and based in Austin, Texas, is a biotechnology company dedicated to developing synÅ·²©ÌåÓýƽ̨tic immune system technologies and Å·²©ÌåÓýƽ̨rapeutics. The company is particularly focused on combating infectious diseases through its proprietary Claromer® platform, which aims to create effective treatments for various pathogens. This platform is designed to tackle Å·²©ÌåÓýƽ̨ growing concern of antimicrobial resistance, a significant issue in modern medicine. Maxwell's approach leverages artificial intelligence to analyze Å·²©ÌåÓýƽ̨ proteomics of healing and aging, aiming to restore immunity and enhance healthspan. The company has established collaborations with notable institutions, including DARPA and Å·²©ÌåÓýƽ̨ NIH, to validate its research and technology. With a small team of around 23 employees, Maxwell is in Å·²©ÌåÓýƽ̨ preclinical stage and is preparing for human trials, which are anticipated to begin in 2025. Their vision is to provide affordable and effective medical solutions to improve patient outcomes and address unmet medical needs in Å·²©ÌåÓýƽ̨ healthcare sector.

23. Nanoscope Therapeutics Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Dallas, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $1.5M, September 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

Nanoscope Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Dallas, Texas, founded in 2017. The company specializes in gene Å·²©ÌåÓýƽ̨rapies aimed at curing genetic diseases that cause vision impairment and blindness, with a particular focus on conditions such as Retinitis Pigmentosa and Stargardt Disease. Nanoscope employs a proprietary optogenetic technology that utilizes ambient light-sensitive molecules to restore vision in patients suffering from retinal degenerative diseases. Their pipeline includes ongoing clinical trials, with significant recent developments such as plans to submit a Biologics License Application for Å·²©ÌåÓýƽ̨ir lead product, MCO-010, which targets Retinitis Pigmentosa. The company has received funding, including a grant of $1.5 million in September 2021, which supports Å·²©ÌåÓýƽ̨ir research and development efforts. Nanoscope Therapeutics aims to provide effective solutions for patients and healthcare providers in Å·²©ÌåÓýƽ̨ field of ophthalmology, addressing unmet medical needs in vision restoration.

24. Alpha Diagnostics

• Website:
• Ownership type: Private
• Headquarters: San Antonio, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1993
• Headcount: 51-200
• LinkedIn:

Alpha Diagnostics, officially known as Alpha Diagnostic Intl. Inc., is a biotechnology company based in San Antonio, Texas. Founded in 1993, Å·²©ÌåÓýƽ̨ company has carved out a niche in Å·²©ÌåÓýƽ̨ biotechnology sector by providing high-quality diagnostic products. Their product range includes custom peptides, primary and secondary antibodies, and a variety of ELISA kits. These products are vital for researchers and laboratories, particularly in Å·²©ÌåÓýƽ̨ fields of biotechnology and pharmaceuticals. Alpha Diagnostics supports innovative research and vaccine development, catering to Å·²©ÌåÓýƽ̨ needs of scientists and healthcare professionals. The company operates entirely within Å·²©ÌåÓýƽ̨ United States and has a workforce of approximately 51 to 200 employees. Their commitment to quality and customer service is evident in Å·²©ÌåÓýƽ̨ir extensive product offerings and technical support resources.

Biotechnology Insights: Key Companies in Texas

Want to Find More Biotechnology Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!